In 2011 two extensive studies were published about prevalence and associated disability, including the associated disease burden and financial costs, of brain diseases in Europe [1, 2, 3]. A shocking finding was that in a European population of more than 400 million people, approximately one-third suffered from a psychiatric or neurological disorder. In the psychiatric disorders, anxiety disorders had the highest 12-month prevalence (14%) and depression (7%), approximately 61.5 million people. The disability burden of psychiatric diseases including major depression is tremendous being defined in disability-adjusted life years (DALYs). In 2010, more than 26% of all cumulated disease burden in Europe was due to brain disorders; depression belongs to the top diseases with the highest DALYs. Major depression is a severe brain disorder associated with long-term disability and low quality of life. Suicide and suicidal attempts are highly associated with depression and have an enormous impact on relatives and society.
Since the 1950s and 1960s of the last century, discovery and development of antidepressants have gradually emerged. Early antidepressants like imipramine and the irreversible monoamine oxidase inhibitors (MAOI) were discovered by serendipity. These “accidental” discoveries have led to intensive research and have led to a series of new antidepressants, like the tricyclic class (TCA, e.g., imipramine, nortriptyline, amitriptyline, and clomipramine) and a series of (both reversible and irreversible) MAOIs. These antidepressants, although still clinically available, are not anymore first-line medicines, mainly because of their sometimes severe side effects. The research in the 1960s and 1970s led to the insight that TCAs block monoamine transporters (reuptake carriers) for serotonin and noradrenaline to varying extent. Some TCAs are preferential serotonin transporter (SERT) blockers (clomipramine, amitriptyline), while others are preferential noradrenaline transporter (NET) blockers (desipramine, maprotiline) or mixed SERT/NET blockers (doxepin, imipramine). TCAs also block several neurotransmitter receptors, particularly muscarinic cholinergic, H1 histaminergic, and α1-adrenoceptors, which is mainly responsible for their (unwanted) side effects, including sedation, dry mouth, and constipation.
Based on the early, but overly simplistic hypothesis that low serotonin and/or noradrenalin levels/activity in the brain are associated (or even causative in) with depression, the development of selective serotonin reuptake inhibitors (SSRIs; fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram) and selective noradrenaline reuptake inhibitors (NRIs; reboxetine, atomoxetine) and mixed 5-HT/NA reuptake blockers (SNRIs: venlafaxine, duloxetine) was enabled. Several other antidepressants have been developed (e.g., bupropion, mirtazapine, agomelatine, trazodone, nefazodone), with variable mechanisms of action. In general, SSRIs are the drugs of choice and first-line in the treatment of major depression . The first SSRIs (zimeldine, fluvoxamine) were introduced in the early 1980s , and in the ensuing decade, several followed (fluoxetine, paroxetine, sertraline). Up to this moment, SSRIs still are first-line medication in MDD, but some breakthrough antidepressants are emerging (esketamine), whereas extensive and intensive research and development are ongoing .
3. Antidepressants: how good are they?
SSRIs like all antidepressants come with associated problems, viz., (1) side effects, (2) limited efficacy, and (3) slow onset of action.
3.1 Side effects
Major depressive disorder (MDD) typically comes in recurrent depressive episodes rather than a single episode. Antidepressant treatment requires to focus on both acute and maintenance aspects of MDD. The primary goal of the acute treatment phase (8–12 weeks) is to achieve symptomatic remission. In the acute phase, emerging side effects of the first-line treatment (often an SSRI) and the tolerance development of the patient strongly co-determine a positive antidepressant response to SSRIs or SNRIs. Main side effects (occurring in approximately 10–30% of patients) are nausea, dry mouth, sweating, sexual dysfunction, somnolence, nervousness, anxiety, dizziness, and insomnia . If SSRI/SNRI treatment is not effective, MAO inhibitors or TCAs (as third-line treatments) may be used, although they come with additional and often more severe side effects. Second-line treatment includes novel antidepressants like vilazodone or vortioxetine or second-generation antidepressants like agomelatine, bupropion, or mirtazapine. All have their own side effect profile and are comparably effective antidepressant compared to SSRIs and others . Lifetime major depression has high psychiatric comorbidity with anxiety disorders, substance use disorders, and impulse control disorders. Many depressed patients have medical (physical) comorbidities requiring pharmacotherapy, and this brings the risk of drug-drug interactions, often associated with cytochrome (CYP) P450 or P-glycoprotein-mediated effects. This may exacerbate side effects of drugs or interfere with the pharmacological action.
The most disturbing side effects of SSRIs and some TCAs (e.g., clomipramine) are those on sexual functioning like libido, orgasm, and arousal problems. In contrast to some other side effects that are prominent in the first phase of treatment, but often diminish upon drug continuation (like nausea and dizziness), sexual side effects do not disappear and are often causing drug discontinuation. MDD itself is already associated with 50–70% enhanced risk of sexual dysfunction (SD), and prescribing antidepressants with inherent effects on sexual behavior strongly enhances the risk for noncompliance or discontinued drug-taking . Such a scenario can be avoided by prescribing (e.g., as second-line choice) antidepressants without (or less) sexual side effects (e.g., agomelatine, bupropion, vilazodone, or vortioxetine). Because depression occurs during all life phases, it is also common during pregnancy with an estimation of 20% of women that experience depressive symptoms during that time , whereas around 4–8% of pregnant women suffer from MDD. Depression of the mother impacts the fetus, e.g., by the enhanced cortisol levels in the mother which also pass the placenta. There is strong evidence that increased stress levels of the mother may lead to neurological and behavioral changes in the child which persists at least into adolescence (e.g., ). In the contribution of Staal and Olivier (Chapter 2), a review is given of the consequences of depression during pregnancy. Although the consequences for a child, adolescent, or adult that was in utero subject to a mother experiencing MDD are not yet completely clear, the first results point to a negative influence . However, nowadays a considerable number (2–3%) of pregnant women with MDD are treated with antidepressants, mostly with SSRIs. SSRIs cross the placenta and reach the fetus, including the central nervous system. Because serotonin plays a key role in embryonic development as a neurotrophic factor, disturbances in its level might lead to (permanent) changes in the offspring [13, 14, 15]. Chapter 2 summarizes the state of the art of the interaction between untreated or SSRI-treated mothers with severe depression. It is not yet clear whether SSRI treatment or not is preferable for depression in pregnant women.
3.2 Limited efficacy
Antidepressants have limited efficacy in relieving depressive symptoms in MDD patients. It is estimated that approximately 50% of depressed patients are adequately treated by the available interventions, including pharmacotherapy . Most patients receiving pharmacotherapy fail to achieve and sustain remission, eventually not leading to functional recovery. The majority of patients starting an antidepressant require several subsequent and different antidepressants or adjunctive therapy (either pharmacological or cognitive behavioral therapy). There is evidence that if a chosen treatment strategy (a certain antidepressant, often an SSRI) results in symptomatic improvement within the first weeks, full remission is likely, but the reverse is also true: lack of early improvement predicts a high chance on non-remittance . After failure of a number of (adequately dosed) antidepressants of different classes (SSRI, TCA, MAOI), and augmentation with various drugs (e.g., antipsychotics) and other strategies (e.g., cognitive behavioral therapy), patients are considered treatment-resistant. Treatment-resistant depression (TRD) is defined as the failure to respond to one or more standard antidepressant treatment trials of adequate dosing and duration [18, 19]. TRD is a big challenge to treat. Although depression is diagnosed as a single entity, MDD  is an extremely heterogeneous disease  with regard to symptoms, etiologies, and pathophysiologies, with some moderately heritable background  and a high susceptibility to adverse life events . TRD reflects a complex, heterogeneous state, probably with multiple causal underlying mechanisms. It is not clear how and where TRD patients differ from non-TRD patients, although early life stress seems to facilitate treatment resistance . Research is clearly needed to establish the pathophysiology of TRD, the complex mechanisms involved, and the heterogeneity of the TRD patient. Unfortunately, depression is presently not a high priority for pharmaceutical companies, due to recent failures in antidepressant discovery and lack of understanding of the mechanisms involved and the consequent lack of available targets. Akil et al.  argue a need of a fundamental approach in the search for new and effective treatments for TRD. They propose to identify dysfunctional brain circuitry in animal models of depression, looking at changes in associated gene expression. Combination of animal research with human genetic and imaging studies must generate circuits and molecules that are both altered in the animal models of TRD and also in selected patient populations. Such translational and highly integrated research may lead to new targets for specific anti-TRD medication.
In Chapter 3 Marek and colleagues describe the research on orexin 2 receptor antagonists as putative new antidepressants. Orexin, a hypothalamic neuropeptide, is known for its involvement in sleep-wake cycling of all mammals, including man. Orexin 2 receptor antagonists produce antidepressant activity in animal tests sensitive for antidepressant activity, including the DRL-72 sec schedule of reinforcement, an advanced screen for antidepressants . Both positive and negative preliminary human data are present on orexin 2 receptor antagonists in depression, but further studies are needed to answer whether this approach might lead to new antidepressants or may be also effective in treatment-resistant depression.
3.3 Slow onset of action
The current most widely prescribed antidepressants, SSRIs and SNRIs, but also TCAs and MAOIs and other antidepressants, have no acute onset of action but work (gradually) over a period of weeks to months. It is still largely unknown what underlying CNS mechanisms are involved in the slow onset of action of antidepressants. In the case of serotonergic antidepressants (SSRIs, SNRIs), a complex interaction between various 5-HT auto- and heteroreceptors as modulators of the SSRI-induced chronic increase in CNS serotonin plays a role . Acute administration of SSRIs Inhibits somatodendritic 5-HT1A autoreceptors leading to inhibition of firing activity of serotonergic neurons and consequently dampened release of 5-HT in the forebrain, which, in some not yet understood way, contributes to the slow onset of action of SSRIs . Desensitization of 5-HT1A autoreceptors after long-term administration might overcome the decrease in 5-HT release and subsequently would lead to high serotonin release . Combining an SSRI and 5-HT1A-receptor antagonist might create a fast onset of action mechanism for antidepressant activity. The lack of availability of clinically approved selective 5-HT1A receptor antagonists led to studies using the mixed β-adrenoceptor/5-HT1A receptor antagonist pindolol together with various SSRIs in MDD patients . In a placebo-controlled study, pindolol increased the antidepressant efficacy of fluoxetine, although no significant improvement in onset of action of the combination was found . Pindolol is probably not the best tool to perform this kind of “onset of action” studies (pindolol is a relatively weak and not a full 5-HT1A receptor antagonist, and its beta-blocking activities induce side effects), but a study with a selective 5-HT1A-receptor antagonist did not find any difference either. It was postulated [30, 31] that two new multi-target antidepressants, vilazodone (SSRI+ partial 5-HT1A receptor agonist) and vortioxetine (SSRI+5-HT1A,1B,1D,7 receptor agonist and 5-HT3 receptor antagonist), might have an advantage over existing drugs in terms of efficacy and onset of antidepressant action, although clinical data thus far have not shown evidence for improving the onset of action [32, 33]. It is evident that antidepressants that primarily act via monoaminergic neurotransmission all share the slow onset of action principle, and new molecules stemming from this “classical” approach will not deliver fast onset of action compounds.
The finding that one single dose of intravenous ketamine produced rapid and sustained antidepressant effects in depressed patients led to a new and exciting opening in this field . Ketamine, an NMDA receptor antagonist and dissociative anesthetic, produces at low doses mild dissociative and psychotomimetic effects but also exerted rather unexpected antidepressant effects. One single dose of ketamine (0.5 mg/kg, intravenously by slow infusion) induced a rapid antidepressant effect (within hours) that lasted for 7 days . Later studies have confirmed the fast antidepressant onset, even in TRD patients . However, notwithstanding the apparent breakthrough in fast treatment of depression, the side effects of ketamine are still troublesome for general use. Recently (March 2019) a nasal preparation of the (S)-enantiomer (esketamine) received FDA approval after successful phase 3 trials. Moreover, new approaches for fast-onset and effective antidepressants via modulation of the glutamatergic-NMDA system are now subject of intense research efforts [6, 36]. One may expect a new range of novel antidepressants with as main attribute a fast onset of action. Whether these new molecules have a higher efficacy (>50% of responding patients) or accordingly lead to less treatment resistance has to be awaited. Moreover, the side effect profile is likely quite different from the classical “monoaminergic” antidepressants. Only large number of well-treated patients will unravel the impact of these side effects. If only the onset of action is improved, the acceptance of such a new antidepressant will strongly depend on its side effect and safety profile.
One of the big items in the research and discovery of new and innovative antidepressants is the availability of animal models that are able to measure “onset of action,” “efficacy,” and “side effects” . Onset of antidepressant action in an animal model is quite difficult to assess. Most animal depression tests are acute, in that they respond immediately to a dose of a certain antidepressant, e.g., forced swim test, tail suspension test, or DRL-72 sec paradigm. Animal depression models that do not respond acutely but only after chronic treatment of the classic antidepressants are rather scarce, although indispensable in the onset of action discovery. One of such models is the olfactory bulbectomized (OBX) rat [37, 38]. OBX leads to stable and lasting changes in behavior after removing the olfactory bulbs . OBX leads within days after ablation to permanent changes in activity, basal body temperature, heart rate and heart rate variability, and stress responsivity . Increased locomotor activity in an open field is an often used simple parameter to measure the effects of antidepressants . In an extensive review on available animal models, olfactory bulbectomy in rodents is considered superior to other animal models to detect onset of action of antidepressants , with a high sensitivity, specificity, and reliability and moderate ease to use the model. The model generated also the possibility to study effects of antidepressant treatment after cessation of treatment . Chronic (14-day) treatment of imipramine (20 mg/kg) or escitalopram (5 and 10 mg/kg) in OBX and sham-operated rats led to reduction of the hyperactivity in an open field by imipramine and escitalopram of the OBX rats, without effects in the control rats. This reduction in hyperactivity of OBX rats induced by chronic administration of antidepressants remained after cessation of treatment and lasted for 10 weeks after imipramine and 6 weeks after escitalopram cessation . We concluded that the OBX-induced changes in the brain state (neuroplasticity) are probably attenuated by chronic antidepressant administration and that these changes are only slowly returning to the previous OBX state. Pramipexole, a dopamine D3/D2 receptor agonist, used to treat Parkinson patients with additional antidepressant activity , indeed exerted antidepressant activity in the OBX model . Pramipexole is also a psychostimulant and induces at higher doses enhanced locomotion itself, thereby interfering with the already enhanced activity of OBX rats. Remarkably, 1 week after cessation of treatment, pramipexole-treated OBX animals still were not hyperactive, similar to imipramine, thereby suggesting that antidepressant effects of drugs can be detected in the OBX model by using this post-cessation antidepressant-like effect . Unpublished studies  found that 3- and 7-day treatment with imipramine (10 mg/kg/day) normalized OBX-induced hyperactivity in the open field. One week after cessation of imipramine treatment, hyperactivity returned, suggesting that longer periods of treatment (14 days) are at least needed to lead to changes in brain neuroplasticity underlying the suppression of OBX-induced behavioral changes. In a complicated experimental design, ketamine (10 mg/kg, IP) was given to OBX and control rats 24 hours before testing in an open field but appeared ineffective . The experimental design did not give a clear cue about the onset of action of antidepressant activity of ketamine, and more directed research into this avenue has to be initiated. Pandey et al.  found that 14-day but not 7-day treatment with ketamine (1 mg/kg/day) reduced hyperactivity induced by olfactory bulbectomy, although combination of escitalopram (10 mg/kg/day) and ketamine (1 mg/kg/day) reduced hyperactivity at both 7 and 14 days. This may be an indication that ketamine in combination with an SSRI may speed up the onset of antidepressant action.
Recently the FDA has approved esketamine as a nasal spray for adjunctive therapy in treatment-resistant depression . Esketamine is indicated for depressed patients that did not respond to at least two oral antidepressant monotherapies. It has to be given together with a newly initiated oral antidepressant under strict supervision of certified medical professionals, because of the potential serious adverse effects of esketamine. The launch of a successful potential anti-TRD medication might be a breakthrough in the treatment of depression.
4. Other applications for antidepressants
Apart from treatment of depression, antidepressants and particularly SSRIs and SNRIs are also widely used for treatment of various anxiety disorders, obsessive compulsive disorders, gambling disorders, posttraumatic stress disorder, and various other psychiatric disorders, including alcohol use disorder.
In obsessive compulsive disorder, SSRIs are partially effective, but in general higher doses are needed, and onset of action (6–8 weeks) is slower than in depression. Because comorbidity of depression and anxiety is very high, it appeared that SSRIs could be used as a rational therapy for both disorders, although the disadvantages of SSRIs in depression (side effects, onset of action, partial efficacy) are comparable in anxiety disorder treatment. In Chapter 4, Ballesta and coworkers review and discuss the role of antidepressants in alcohol use disorder (AUD). Because a strong relationship exists between major depression and AUD, the authors investigated the potential role of hippocampal plasticity and neurogenesis in both disorders. By integrating the knowledge of plasticity changes in the hippocampus and its role in both disorders, the authors try to implement shared mechanisms. It is clear that considerable research efforts, both preclinical and clinical, are needed to advance our possibilities to better treat both depression and alcohol use disorder.
The emergence of effective antidepressants in the 1960s and 1970s of the last century has led to an explosion of new and often unexpected new discoveries and clinical applications. The development of SSRIs after the serendipitous detection of the first tricyclic antidepressants has revolutionized the treatment of major depression but has also led to new treatments of various anxiety disorders, obsessive compulsive disorder, and various other psychiatric conditions.
Drug treatment always leads to side effects that can be quite cumbersome and often lead to drug discontinuation. Treatment resistance (TRD) is frequently occurring in major depression, and a substantial part of depressed patients (about 30%) does not respond to any treatment. Recent developments (esketamine) promise new approaches in the treatment of TRD although side effects remain a big obstacle.
Research into new and better antidepressants remains urgent but depends primarily on better understanding of the brain mechanisms involved in normal “mood” processing and understanding what is wrong in “depressed” brains. Animal models with high predictive and construct validity are urgently needed to help to discover these (dys)functional mechanisms and deliver new targets for better antidepressants.
Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology. 2011; 21:655-679
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Berghi E, et al. Cost of disorders of the brain in Europe 2010. European Neuropsychopharmacology. 2011; 21:717-778
Nutt DJ. The full cost and burden of disorders of the brain in Europe exposed for the first time. European Neuropsychopharmacology. 2011; 21:715-717
Balon R. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. The American Journal of Psychiatry. 2006; 163:1504-1509
Olivier B. Serotonin: A never-ending story. European Journal of Pharmacology. 2015; 753:2-18
Duman RS, Shinohara R, Fogaça MV, Hare B. Neurobiology of rapid-acting antidepressants: Convergent effects on GluA1-synaptic function. Molecular Psychiatry. 2019. DOI: 10.1038/s41380-019-0400-x
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. CANMAT depression work group. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Canadian Journal of Psychiatry. 2016; 61(9):540-560. DOI: 10.1177/0706743716659417.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry. 2006; 163(11):1905-1917
Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Therapeutic Advances in Psychopharmacology. 2018; 8(1):13-23
Ryan D, Milis L, Misri N. Depression during pregnancy. Canadian Family Physician. 2005; 51:1087-1093
Hutchison SM, Mâsse LC, Brain U, Oberlander TF. A 6-year longitudinal study: Are maternal depressive symptoms and selective serotonin reuptake inhibitor (SSRI) antidepressant treatment during pregnancy associated with everyday measures of executive function in young children? Early Human Development. 2019; 128:21-26. DOI: 10.1016/j.earlhumdev.2018.10.009
Houwing DJ, Staal L, Swart JM, Ramsteijn AS, Wöhr M, de Boer SF, et al. Subjecting dams to early life stress and perinatal fluoxetine treatment differentially alters social behavior in young and adult rat offspring. Frontiers in Neuroscience. 2019; 13:229. DOI: 10.3389/fnins.2019.00229
Weissman MM. Postpartum depression and its long-term impact on children: Many new questions. JAMA Psychiatry. 2018; 75(3):227-228. DOI: 10.1001/jamapsychiatry.2017.4265
Malm H, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW, et al. Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: A National Register-Based Study. Journal of the American Academy of Child and Adolescent Psychiatry. 2016; 55(5):359-366. DOI: 10.1016/j.jaac.2016.02.013
Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: News from mouse molecular genetics. Nature Reviews Neuroscience. 2003; 4:1002-1012
McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, et al. Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders. 2014; 156:1-7. DOI: 10.1016/j.jad.2013.10.043
Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: The impact of early symptomatic improvement. Canadian Journal of Psychiatry. 2012; 57(12):782-788
Papakostas GI, Ionescu DF. Towards new mechanisms: An update on therapeutics for treatment-resistant major depressive disorder. Molecular Psychiatry. 2015; 20(10):1142-1150. DOI: 10.1038/mp.2015.92
Fava M. Diagnosis and definition of treatment-resistant depression. Biological Psychiatry. 2003; 53(8):649-659
DSM5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013
Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, et al. Treatment resistant depression: A multi-scale, systems biology approach. Neuroscience and Biobehavioral Reviews. 2018; 84:272-288. DOI: 10.1016/j.neubiorev.2017.08.019
Geschwind DH, Flint J. Genetics and genomics of psychiatric disease. Science. 2015; 349(6255):1489-1494. DOI: 10.1126/science.aaa8954
Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nature Reviews Disease Primers. 2016; 2:16065. DOI: 10.1038/nrdp.2016.65
Williams LM. Precision psychiatry: A neural circuit taxonomy for depression and anxiety. Lancet Psychiatry. 2016; 3(5):472-480. DOI: 10.1016/S2215-0366(15)00579-9
O’Donnell JM, Marek GJ, Seiden LS. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neuroscience and Biobehavioral Reviews. 2005; 29(4-5):785-798
Nautiyal KM, Hen R. Serotonin receptors in depression: From A to B. F1000Res. 2017; 6:123. DOI: 10.12688/f1000research.9736.1. eCollection 2017
Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends in Neurosciences. 1996; 19(9):378-383
Artigas F, Schenker E, Celada P, Spedding M, Lladó-Pelfort L, Jurado N, et al. Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS. Nature Reviews Drug Discovery. 2017; 16(1):1-2. DOI: 10.1038/nrd.2016.205
Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of Pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997; 349:1594-1597
Scorza MC, Lladó-Pelfort L, Oller S, Cortés R, Puigdemont D, Portella MJ, et al. Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment. British Journal of Pharmacology. 2012; 167(5):1021-1034. DOI: 10.1111/j.1476-5381.2011.01770.x
Artigas F, Bortolozzi A, Celada P. Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies. European Neuropsychopharmacology. 2018; 28(4):445-456. DOI: 10.1016/j.euroneuro.2017.10.032
Stuivenga M, Giltay EJ, Cools O, Roosens L, Neels H, Sabbe B. Evaluation of vilazodone for the treatment of depressive and anxiety disorders. Expert Opinion on Pharmacotherapy. 2019; 20(3):251-260. DOI: 10.1080/14656566.2018.1549542
Gonda X, Sharma SR, Tarazi FI. Vortioxetine: A novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery. 2019; 14(1):81-89. DOI: 10.1080/17460441.2019.1546691
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 2000; 47(4):351-354
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006; 63(8):856-864
Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: Highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacology & Therapeutics. 2019;(pii):S0163-7258(19)30040-3. DOI: 10.1016/j.pharmthera.2019.02.017
Ramaker MJ, Dulawa SC. Identifying fast-onset antidepressants using rodent models. Molecular Psychiatry. 2017; 22(5):656-665. DOI: 10.1038/mp.2017.36
Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neuroscience and Biobehavioral Reviews. 2005; 29(4-5):627-647
Vinkers CH, Breuer ME, Westphal KGC, Korte SM, Oosting RS, Olivier B, et al. Olfactory bulbectomy induces rapid and stable changes in basal and stress-induced locomotor activity, heart rate and body temperature responses in the home cage. Neuroscience. 2009; 159:39-46
Breuer ME, Groenink L, Oosting RS, Westenberg HGM, Olivier B. Long-term behavioral changes after cessation of chronic anti-depressant treatment in olfactory bulbectomized rats. Biological Psychiatry. 2007; 61:990-995
Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Depression/Parkinson Italian study group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: A national multicenter parallel-group randomized study. Journal of Neurology. 2006; 253(5):601-607
Breuer ME, Groenink L, Oosting RS, Buerger E, Korte SM, Ferger B, et al. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist in olfactory bulbectomized rats. European Journal of Pharmacology. 2009; 616:134-140
Breuer ME. Depression’s next top model: Pharmacology of olfactory bulbectomy-induced behaviors [Ph.D. thesis]. Utrecht; 2009. pp. 1-185
Holubova K, Kleteckova L, Skurlova M, Ricny J, Stuchlik A, Vales K. Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner. Psychopharmacology. 2016; 233(11):2077-2097. DOI: 10.1007/s00213-016-4256-3
Pandey DK, Bhatt S, Jindal A, Gautam B. Effect of combination of ketanserin and escitalopram on behavioral anomalies after olfactory bulbectomy: Prediction of quick onset of antidepressant action. Indian Journal of Pharmacology. 2014; 46(6):639-643. DOI: 10.4103/0253-7613.144935
Sancar F. New therapy for treatment-resistant depression. Journal of the American Medical Association. 2019; 321(15):1449. DOI: 10.1001/jama.2019.3596